Chemed (CHE) Q1 2026 earnings review
A Tale of Two Companies: VITAS Surges While Roto-Rooter Sinks
Chemed delivered a mixed quarter that was heavily skewed by divergent segment performance. Consolidated revenue grew a tepid 1.6%, while GAAP Net Income actually fell 7.6%. However, aggressive share repurchases masked the bottom-line decay, allowing Adjusted EPS to tick up 0.4%. The real story is the internal split: VITAS recovered from its Medicare Cap woes much faster than anticipated, driving an unexpected guidance hike. Meanwhile, Roto-Rooter continues to decelerate into negative growth territory, plagued by weather disruptions and a structural margin squeeze from skyrocketing Google search costs.
🐂 Bull Case
Management's strategy to rebalance the VITAS patient mix worked remarkably fast. Revenue grew 3.1%, Admissions jumped 6.9%, and the segment completely avoided Florida Medicare Cap billing limitations in Q1, prompting an upward revision to full-year guidance.
Chemed repurchased an astounding 500,000 shares for $197.7 million in Q1 alone. This 7.2% reduction in the share base artificially inflates EPS and provides a strong floor for the stock price.
🐻 Bear Case
Roto-Rooter's adjusted EBITDA margin plummeted 218 basis points to 22.5%. The shift toward expensive paid internet leads is permanent, completely wiping out the margin profile the company enjoyed historically.
Despite a 3.3% increase in total leads, Roto-Rooter revenue fell 0.9%. Commercial water restoration collapsed 10.0% and residential water restoration dropped 11.8%, indicating severe pricing or closure rate issues.
⚖️ Verdict: ⚪
Neutral. The core healthcare business (VITAS) is executing flawlessly and throwing off cash, but the plumbing segment (Roto-Rooter) is fundamentally broken at the moment. The massive EPS guidance hike is a mirage largely manufactured by extreme stock buybacks rather than holistic organic growth.
Key Themes
VITAS Patient Mix Rebalancing
After intentionally choking growth in 2025 to avoid massive Medicare Cap penalties, VITAS has successfully normalized its patient mix. Average Daily Census (ADC) grew an Accelerating 2.2% and Admissions surged 6.9%. Management confirmed that initiatives to return to normal growth were 'more quickly successful than originally anticipated,' entirely eliminating Florida cap accruals for Q1.
Roto-Rooter's Phantom Growth Narrative
Management maintained full-year Roto-Rooter revenue guidance of 3.0% to 3.5%, implying an Accelerating trend for the rest of the year. This directly contradicts the Q1 data: revenue contracted by 0.9%, commercial excavation fell 7.8%, and revenue from independent contractors dropped 3.3%. Achieving 3%+ growth for the year will require a massive and currently invisible turnaround.
Google Algorithms Crush Margins
A structural shift in digital marketing technology continues to compress Roto-Rooter's margins. Due to changes in Google's search algorithms, the business can no longer rely on organic search and is forced to buy expensive paid leads. While total leads increased 3.3%, marketing expenses exceeded expectations by $2.0 million, forcing management to lower full-year margin guidance.
Macro Impact: Winter Weather Disruptions
Unusual ice and snowstorms forced 24 Roto-Rooter branches to suspend service for five days during the quarter. This macro headwind resulted in an estimated net revenue loss of $3 million to $4 million, exacerbating the segment's already weak volume.
Strategic Franchise Acquisitions
Inorganic growth is stepping in to save Roto-Rooter's top line. On March 31, Chemed spent $20.6 million to acquire franchises in San Francisco and Fort Worth. These territories cover 3.3 million people and are projected to inject an immediate $5.0 million to $5.5 million in revenue through the remainder of 2026.
Other KPIs
Accelerating dramatically. Chemed repurchased 500,000 shares in a single quarter at an average price of $395.36. To put this in perspective, this single-quarter buyback exceeds the company's entire historical quarterly run-rate and artificially propped up Adjusted EPS, which would have otherwise tracked the 7.6% drop in GAAP Net Income.
Chemed took on $91.2 million in long-term debt to help fund the massive Q1 share buybacks and franchise acquisitions. In April 2026, they inked a new five-year $450 million credit facility (with a $250 million expansion feature) at SOFR + 100 bps, ensuring ample liquidity for further capital deployment.
Guidance
Accelerating. The midpoint represents a 13% increase from FY25's $21.55. This was revised upward from the original $23.25-$24.25 range, driven heavily by the reduced share count and the faster-than-expected recovery at VITAS.
Accelerating. Revised upward from the original 5.5%-6.5% guidance. Management expects ADC growth of 4.5% to 5.5% as the admission mix normalizes without triggering new cap penalties.
Reversing. Maintained from prior guidance despite a -0.9% contraction in Q1. The achievement of this target relies heavily on the $5.5 million inorganic boost from the newly acquired California and Texas franchises rather than core organic growth.
Decelerating. Lowered slightly from the original 22.5%-23.0% expectation. Management explicitly conceded that elevated internet marketing costs are expected to persist for the remainder of the year.
Key Questions
Roto-Rooter Organic Growth Reality
You maintained Roto-Rooter's full-year revenue guidance of 3.0% to 3.5% despite a 0.9% contraction in Q1. Excluding the $5.0-$5.5 million expected from the new San Francisco and Fort Worth franchises, what is the implied organic growth rate for the rest of the year?
The Floor for Roto-Rooter Margins
With the structural shift toward expensive paid Google search leads causing a $2 million expense surprise this quarter, is the revised 21.5%-22.5% EBITDA margin guidance the new permanent reality, or is there a viable path back to the historical 24%+ margins?
VITAS Acuity Mix Strategy
VITAS recovered faster than anticipated, allowing you to avoid the Florida Medicare cap in Q1. As your cap cushion continues to grow, will you intentionally pivot back toward highly profitable, longer-stay patients, or is the current acuity mix the permanent operational model?
Capital Allocation Priority
You deployed nearly $200 million on buybacks in a single quarter and secured a new $450 million credit facility. Is this aggressive pace of share repurchases expected to continue, or was Q1 an opportunistic acceleration?